|Bid||150.00 x 1000|
|Ask||165.00 x 100|
|Day's Range||148.75 - 150.63|
|52 Week Range||95.80 - 163.75|
|PE Ratio (TTM)||22.68|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||184.18|
DUBLIN, May 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will host a webcast to discuss data to be presented on JZP-110 and Xyrem® (sodium oxybate) oral solution during the Associated Professional Sleep Societies (APSS) Annual Meeting taking place from June 3-7, 2017 in Boston, MA. The live webcast will begin at 7:00 p.m. EDT on June 6, 2017. The webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.
DUBLIN, Ireland, May 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that twelve abstracts supporting the company's sleep medicine portfolio, including data on its investigational ...
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).